First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and to determine the maximum tolerable dose (MTD) and/or recommended phase 2 dose (RP2D) of HH30134 administered orally on a continuous once daily (QD) schedule in adults patients with advanced solid tumors.

Timeline

Start

2021-04-08

Primary completion

2023-03-24

Completion

2023-03-24

Outcome

Outcome not reported

Stopped (Business): “Sponsor business decision”

Drugs

Indications